cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: Homeostatic role of VIP

Inflammatory Bowel Diseases

Volumn 11, Issue 7, 2005, Pages 674-684

  Abad, Catalina ^a   Juarranz, Yasmina ^a   Martinez, Carmen ^a   Arranz, Alicia ^a   Rosignoli, Florencia ^a   García Gómez, María ^a   Leceta, Javier ^a   Gomariz, Rosa P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

2,4,6 trinitrobencene sulfonic acid; Crohn's disease; Inflammation; Microarray; Vasoactive intestinal peptide

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR2; COMPLEMENTARY DNA; CX3C CHEMOKINE; CX3CL1 CHEMOKINE; CXCL13 CHEMOKINE; CXCL14 CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; MESSENGER RNA; STROMAL CELL DERIVED FACTOR 1; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DNA MICROARRAY; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL MODEL; HOMEOSTASIS; IMMUNOPATHOLOGY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TH1 CELL;

ANALYSIS OF VARIANCE; ANIMALS; CHEMOKINES; CROHN DISEASE; CYTOKINES; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED BALB C; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, IMMUNOLOGIC; TRINITROBENZENESULFONIC ACID; VASOACTIVE INTESTINAL PEPTIDE;

EID: 21844436593     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MIB.0000171872.70738.58     Document Type: Article

References (75)

1. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
2. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;1:1281-1290.
3. Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology. 2004;126:1574-1581.
4. Shanahan F. Crohn's disease. Lancet. 2002;5:62-69.
5. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal Peptide in immunomodulation. Pharmacol Rev. 2004;56:249-290.
6. Gomariz RP, Martinez C, Abad C, et al. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des. 2001;7:89-111.
7. Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J Mol Med. 2002;80:16-24.
8. Abad C, Martinez C, Juarranz MG, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003;124:961-971.
9. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000; 25:169-193.
10. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol. 2004; 22:891-928.
11. Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36:1882-1886.
12. Ajuebor MN, Zagorski J, Kunkel SL, et al. Contrasting roles for CXCR2 during experimental colitis. Exp Mol Pathol. 2004;76:1-8.
13. Laing KJ, Secombes CJ. Chemokines. DevComp Immunol. 2004;28:443-460.
14. Dale M, Nicklin MJ. Interleukin-1 receptor cluster: gene organization of ILR2, ILR1, IL1RL2 (IL-1Rrp2), IL1RL1 (T1/ST2), and IL-18R1 (IL-1Rrp) on human chromosome 2q. Genomics. 1999;57:177-179.
15. Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004;172: 3983-3988.
16. Ito H. IL-6 and Crohn's disease. Curr Drug Targets Inflamm Allergy. 2003; 2:125-130.
17. Holub MC, Mako E, Devay T, et al. Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease. Scand J Gastroenterol Suppl. 1998;228:47-50.
18. Liu Z, Geboes K, Colpaert S, et al. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol. 2000;164:3608-3615.
19. Moseley TA, Haudenschild DR, Rose L, et al. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155-174.
20. Witowski J, Ksiazek K, Jorres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci. 2004;61:567-579.
21. Li H, Chen J, Huang A, et al. Cloning and characterization of IL-17B and IL-17C, two new members of the IL-17 cytokine family. Proc Natl Acad Sci USA. 2000;97:773-778.
22. Collins M, Whitters MJ, Young DA. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol Res. 2003;28:131-140.
23. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985-995.
24. Howarth GS, Shoubridge CA. Enhancement of intestinal growth and repair by growth factors. Curr Opin Pharmacol. 2001;1:568-574.
25. Dinarello CA. Pro-inflammatory cytokines. Chest. 2000;118:503-508.
26. Weninger W, Carlsen HS, Goodarzi M, et al. Naïve T cell recruitment to nonlymphoid tissues: a role for endothelium-expressed CC chemokine ligand 21 in autoimmune disease and lymphoid neogenesis. J Immunol. 2003;170:4638-4648.
27. Varona R, Cadenas V, Flores J, et al. CCR6 has a non-redundant role in the development of inflammatory bowel disease. Eur J Immunol. 2003;33: 2937-2946.
28. Luster AD. The role of chemokines in linking innate and adaptive immunity. Curr Opin Immunol. 2002;14:129-135.
29. Moser B, Schaerli P, Loetscher P. CXCR5+ T cells: follicular homing takes center stage in T-helper-cell responses. Trends Immunol. 2002;23: 250-254.
30. Moser B, Wolf M, Walz A, et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 2004;25:75-84.
31. Muller G, Hopken UE, Lipp M. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev. 2003; 195:117-135.
32. Muller G, Lipp M. Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafficking. Microcirculation. 2003;10:325-334.
33. Obermeier F, Schwarz H, Dunger N, et al. OX40/OX40L interaction induces the expression of CXCR5 and contributes to chronic colitis induced by dextran sulfate sodium in mice. Eur J Immunol. 2003;33: 3265-3274.
34. Carlsen HS, Baekkevold ES, Morton HC, et al. Monocyte-like and mature macrophages produce CXCL13 (B-cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104:3021-3027.
35. Jo Y, Matsumoto T, Yada S, et al. CCR4 is an up-regulated chemokine receptor of peripheral blood memory CD4+ T cells in Crohn's disease. Clin Exp Immunol. 2003;132:332-338.
36. Papadakis KA, Landers C, Prehn J, et al. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol. 2003;171:159-165.
37. Romagnani P, Lasagni L, Annunziato F, et al. CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 2004;25:201-209.
38. Watford WT, Moriguchi M, Morinobu A, et al. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003;14:361-368.
39. Parnet P, Garka KE, Bonnert TP, et al. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem. 1996;271:3967-3970.
40. Monteleone G, Trapasso F, Parrello T, et al. Bioactive IL-18 expression is up-regulated in Crohn's disease. J Immunol. 1999;163:143-147.
41. Camoglio L, Te Velde AA, Tigges AJ, et al. Altered expresion of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm Bowel Dis. 1998;4:285-290.
42. Kitamura K, Nakamoto Y, Kaneko S, et al. Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis. J Leukoc Biol. 2004;76:1111-1117.
43. Maerten P, Shen C, Colpaert S, et al. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol. 2004;135:310-317.
44. Schreiber S, Nikolaus S, Hampe J, et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet. 1999;353:459-461.
45. Pallone F, Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut. 1998;43:735-736.
46. McCormack G, Moriarty D, O'Donoghue DP, et al. Tissue cytokine and chemokine expression in inflammatory bowel disease. Inflamm Res. 2001; 50:491-495.
47. Papadakis KA. Chemokines in inflammatory bowel disease. Curr Allergy Asthma Rep. 2004;4:83-89.
48. Newman R, Cuan N, Hampartzoumian T, et al. Vasoactive intestinal peptide impairs leukocyte migration but fails to modify experimental murine colitis. Clin Exp Immunol. 2005;139:411-420.
49. Elson CO, Sartor RB, Tennyson GS, et al. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109:1344-1367.
50. Liu H, Pope RM. Phagocytes: mechanisms of inflammation and tissue destruction. Rheum Dis Clin North Am. 2004;30:19-39.
51. Stallmach A, Giese T, Schmidt C, et al. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis. 2004;19:308-315.
52. Sun FF, Lai PS, Yue G, et al. Pattern of cytokine and adhesion molecule mRNA in hapten-induced relapsing colon inflammation in the rat. Inflammation. 2001;25:33-45.
53. Hendel J, Nielsen OH. Expression of cyclooxygenase-2 mRNA in active inflammatory bowel disease. Am J Gastroenterol. 1997;92:1170-1173.
54. Khan I, Al-Awadi FM, Thomas N, et al. Cyclooxygenase-2 inhibition and experimental colitis: beneficial effects of phosphorothioated antisense oligonucleotide and meloxicam. Scand J Gastroenterol. 2002;37:1428-1436.
55. Dinarello CA. The IL-I family and inflammatory diseases. Clin Exp Rheumatol. 2002;20:S1-13.
56. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790-804.
57. Claria J. Cyclooxygenase-2 biology. Curr Pharm Des. 2003;9:2177-2190.
58. Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999;162:1200-1205.
59. Delgado M, Abad C, Martinez C, et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001;7:563-568.
60. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol. 2000;19: 51-62.
61. Bamias G, Sugawara K, Pagnini C, et al. The Th1 immune pathway as a therapeutic target in Crohn's disease. Curr Opin Investig Drugs. 2003; 4:1279-1286.
62. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75:163-189.
63. Blaschke S, Koziolek M, Schwarz A, et al. Pro-inflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol. 2003;30: 1918-1927.
64. Muehlhoefer A, Saubermann LJ, Gu X, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol. 2000;164:3368-3376.
65. Rector A, Vermeire S, Thoelen I, et al. Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet. 2001;108:190-193.
66. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
67. Maerten P, Shen C, Colpaert S, et al. Involvement of interleukin 18 in Crohn's disease: evidence from in vitro analysis of human gut inflammatory cells and from experimental colitis models. Clin Exp Immunol. 2004;135:310-317.
68. Stallmach A, Marth T, Weiss B, et al. An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. Gut. 2004;53: 339-345.
69. Gounni AS, Hamid Q, Rahman SM, et al. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol. 2004; 173:2771-2779.
70. Grimm MC, Newman R, Hassim Z, et al. Vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J Immunol. 2003;171:4990-4994.
71. Delgado M. VIP: a very important peptide in T helper differentiation. Trends Immunol. 2003;24:221-224.
72. Hunter MM, McKay DM. Review article: helminths as therapeutic agents for inflammatory bowel disease. Aliment Pharmacol Ther. 2004;19:167-177.
73. Ruddle NH. Lymphoid neo-organogenesis: lymphotoxin's role in inflammation and development. Immunol Res. 1999;19:119-125.
74. Hjelmstrom P. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol. 2001;69:331-339.
75. Pablos JL, Santiago B, Galindo M, et al. Synoviocyte-derived CXCL12 is displayed on endothelium and induces angiogenesis in rheumatoid arthritis. J Immunol. 2003;170:2147-2152.